 |
 | Vissza |
Iliás Ákos; Szántó Kata; Gönczi Lóránt; Kürti Zsuzsanna; Golovics Petra Anna; Farkas Klaudia; Szepes Zoltán; Szalay Balázs; Vincze Áron; Molnár Tamás; Lakatos Péter László:
Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 17 (12).
pp. 2506-2513.
ISSN 1542-3565
(2019)
Rencz Fanni; Lakatos Péter László; Gulácsi László; Brodszky Valentin; Kürti Zsuzsanna; Herszényi László; Molnár Tamás; Péntek Márta; Palatka Károly:
Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease.
QUALITY OF LIFE RESEARCH, 28 (1).
pp. 141-152.
ISSN 0962-9343
(2019)
Bálint Anita; Rutkai Mariann; Kolar Martin; Bortlik Martin; Duricovad Dana; Hruba Veronika; Lukas Milan; Mitrova Katarina; Malickova Karin; Lukas Martin; Szepes Zoltán; Nagy Ferenc; Palatka Károly; Lovas Szilvia; Végh Zsuzsanna; Kürti Zsuzsanna; Csontos Ágnes Anna; Miheller Pál; Nyári Tibor András; Bor Renáta; Milassin Ágnes; Fábián Anna; Szántó Kata; Lakatos Péter László; Molnár Tamás; Farkas Klaudia:
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
EXPERT OPINION ON BIOLOGICAL THERAPY, 18 (11).
pp. 1181-1187.
ISSN 1471-2598
(2018)
Gönczi Lóránt; Kürti Zsuzsanna; Rutka Mariann; Végh Zsuzsanna; Farkas Klaudia; Lovász Barbara Dorottya; Golovics Petra Anna; Gecse Krisztina Barbara; Szalay Balázs; Molnár Tamás; Lakatos Péter László:
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
BMC GASTROENTEROLOGY, 17 (1).
Azonosító: 97.-Terjedelem: 7 p..
ISSN 1471-230X
(2017)
Bálint Anita; Rutka Mariann; Végh Zsuzsanna; Kürti Zsuzsanna; Gecse Krisztina Barbara; Lakatos László; Szepes Zoltán; Vincze Áron; Bor Renáta; Milassin Ágnes; Fábián Anna; Nagy Ferenc; Lakatos Péter László; Molnár Tamás; Farkas Klaudia:
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
EXPERT OPINION ON DRUG SAFETY, 16 (8).
pp. 885-890.
ISSN 1474-0338
(2017)
Farkas Klaudia; Rutka Mariann; Ferenci Tamás; Nagy Ferenc; Bálint Anita; Bor Renáta; Milassin Ágnes; Fábián Anna; Szántó Kata; Végh Zsuzsanna; Kürti Zsuzsanna; Lakatos Péter László; Szepes Zoltán; Molnár Tamás:
Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center.
EXPERT OPINION ON BIOLOGICAL THERAPY, 17 (11).
pp. 1325-1332.
ISSN 1471-2598
(2017)
Gönczi Lóránt; Gecse Krisztina Barbara; Végh Zsuzsanna; Kürti Zsuzsanna; Rutka Mariann; Farkas Klaudia; Golovics Petra Anna; Lovász Barbara Dorottya; Banai János; Bene László; Gasztonyi Beáta; Kristóf Tünde; Lakatos László; Miheller Pál; Nagy Ferenc:
Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort.
INFLAMMATORY BOWEL DISEASES, 23 (11).
pp. 1908-1915.
ISSN 1078-0998
(2017)
Kürti Zsuzsanna; Lovász Barbara Dorottya; Gecse Krisztina Barbara; Bálint Anita; Farkas Klaudia; Morocza-Szabó Ágnes; Gyurcsányi András; Kristóf Attila; Végh Zsuzsanna; Gönczi Lóránt; Kiss Lajos Sándor; Golovics Petra Anna; Lakatos László; Molnár Tamás; Lakatos Péter László:
Tuberculin skin test and Quantiferon in BCG vaccinated; immunosuppressed patients with moderate-to-severe inflammatory bowel disease.
Journal of Gastrointestinal and Liver Diseases, 24 (4).
pp. 467-472.
ISSN 1841-8724
(2015)
Mandel Michael D.; Bálint Anita; Lovász Barbara Dorottya; Gulácsi László; Strbák Bálint; Golovics Petra Anna; Farkas Klaudia; Kürti Zsuzsanna; Szilágyi Blanka K.; Mohás Anna; Molnár Tamás; Lakatos Péter László:
Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.
European Journal of Health Economics, 15 (Suppl. 1.).
S121-S128.
ISSN 1618-7598
(2014)
